IDEXX LABORATORIES INC /DE Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
IDEXX LABORATORIES INC /DE (IDXX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 121.00 thousand shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-16.
Discontinued › Income Statement
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2022-02-16
- IDEXX LABORATORIES INC /DE antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2014-09-30 was 365.00K shares, a 34.94% decline year-over-year.
- IDEXX LABORATORIES INC /DE antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2014-06-30 was 351.00K shares, a 46.17% decline year-over-year.
- IDEXX LABORATORIES INC /DE antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2013-09-30 was 561.00K shares.
- IDEXX LABORATORIES INC /DE antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2013-06-30 was 652.00K shares, a 13.87% decline year-over-year.
- IDEXX LABORATORIES INC /DE antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 121.00K shares, a 41.26% decline from fiscal 2020.
- IDEXX LABORATORIES INC /DE antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 206.00K shares, a 3.00% increase from fiscal 2019.
- IDEXX LABORATORIES INC /DE antidilutive securities excluded from computation of earnings per share, amount for fiscal 2019 was 200.00K shares, a 30.31% decline from fiscal 2018.
- IDEXX LABORATORIES INC /DE antidilutive securities excluded from computation of earnings per share, amount for fiscal 2018 was 287.00K shares, a 12.23% decline from fiscal 2017.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | 121.00K shares 10-K · filed 2022-02-16 | ||||
| 2020-12-31 | 206.00K shares 10-K · filed 2022-02-16 | ||||
| 2019-12-31 | 200.00K shares 10-K · filed 2022-02-16 | ||||
| 2018-12-31 | 287.00K shares 10-K · filed 2021-02-12 | ||||
| 2017-12-31 | 327.00K shares 10-K · filed 2020-02-14 | ||||
| 2016-12-31 | 88.00K shares 10-K · filed 2019-02-15 | ||||
| 2015-12-31 | 644.00K shares 10-K · filed 2018-02-16 | ||||
| 2014-12-31 | 644.00K shares 10-K · filed 2017-02-17 | 322.00K shares 10-K · filed 2015-02-17 | |||
| 2014-09-30 | 365.00K shares 10-Q · filed 2014-10-24 | 311.00K shares 10-Q · filed 2014-10-24 | |||
| 2014-06-30 | 351.00K shares 10-Q · filed 2014-07-25 | 284.00K shares 10-Q · filed 2014-07-25 | |||
| 2013-12-31 | 1.05M shares 10-K · filed 2016-02-17 | 527.00K shares 10-K · filed 2014-02-18 | |||
| 2013-09-30 | 561.00K shares 10-Q · filed 2014-10-24 | 530.00K shares 10-Q · filed 2014-10-24 | |||
| 2013-06-30 | 652.00K shares 10-Q · filed 2014-07-25 | 556.00K shares 10-Q · filed 2014-07-25 | |||
| 2012-12-31 | 696.00K shares 10-K · filed 2015-02-17 | ||||
| 2012-06-30 | 757.00K shares 10-Q · filed 2012-07-20 | 689.00K shares 10-Q · filed 2012-07-20 | |||
| 2011-12-31 | 597.00K shares 10-K · filed 2014-02-18 | ||||
| 2011-06-30 | 617.00K shares 10-Q · filed 2012-07-20 | 513.00K shares 10-Q · filed 2012-07-20 | |||
| 2010-12-31 | 501.00K shares 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |